{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:00:36Z","timestamp":1792130436797,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To describe real-life data from wet age-related macular degeneration (AMD) patients treated with anti-vascular endothelial growth factors (VEGFs) and to compare our results with previous studies and clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective monocentric cohort study analyzed 865 eyes of 780 wet-AMD patients treated with an anti-VEGF treat-and-extend regimen over a long-term follow-up period. Aflibercept and Ranibizumab were considered first-line agents whereas Bevacizumab was reserved for use on a compassionate basis in patients not meeting treatment criteria. All patients underwent a best corrected visual acuity (BCVA) assessment at each follow-up visit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One-year follow-up figures were available for 82.5% of patients, whilst follow-up data was recorded for 55.6%, 37.6%, 25.1%, and 15.0% of the cohort at years 2, 3, 4, and 5 respectively. Patients treated with Bevacizumab received fewer yearly injections than those treated with Ranibizumab. However, no significant difference in the number of injections per year was detected in other comparisons between groups. Whilst our data showed no significant difference in mean BCVA between the three groups, there was a gradual deterioration of visual function over time for the patient cohort as a whole.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>No significant differences between the 3 anti-VEGF molecules were recorded in wet-AMD patients in real-life conditions. Despite the long-term therapy, we found a slight reduction in visual function especially after the third year of treatment.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12886-021-02055-6","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T18:20:48Z","timestamp":1628965248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study"],"prefix":"10.1186","volume":"21","author":[{"given":"Paolo","family":"Corazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Maria","family":"D\u2019Alterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamil","family":"Kabbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa Mohamed Ragheb","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry Otway","family":"Orlans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Younis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,14]]},"reference":[{"issue":"4","key":"2055_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archopht.122.4.477","volume":"122","author":"N Congdon","year":"2004","unstructured":"Congdon N, O\u2019Colmain B, Klaver CC, Klein R, Mu\u00f1oz B, Friedman DS, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477\u201385.","journal-title":"Arch Ophthalmol"},{"key":"2055_CR2","doi-asserted-by":"crossref","unstructured":"Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, Jonas JB, Keeffe J, Leasher J, Naidoo K, Pesudovs K, Resnikoff S, Taylor HR; Vision Loss Expert Group. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013;1(6):e339\u201349.","DOI":"10.1016\/S2214-109X(13)70113-X"},{"key":"2055_CR3","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","volume":"291","author":"NM Bressler","year":"2004","unstructured":"Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900\u20131.","journal-title":"JAMA"},{"key":"2055_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/00006982-200312000-00001","volume":"23","author":"JD Gass","year":"2003","unstructured":"Gass JD, Agarwal A, Lavina AM, Tawansy KA. Focal inner retinal hemorrhages in patients with drusen: an early sign of occult choroidal neovascularization and chorioretinal anastomosis. Retina. 2003;23:741\u201351.","journal-title":"Retina"},{"key":"2055_CR5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1126\/science.6823562","volume":"219","author":"DR Senger","year":"1983","unstructured":"Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983\u20135.","journal-title":"Science"},{"key":"2055_CR6","doi-asserted-by":"crossref","unstructured":"Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997;13(1):37\u201350.","DOI":"10.1002\/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K"},{"key":"2055_CR7","doi-asserted-by":"crossref","unstructured":"Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40(3):352\u201368.","DOI":"10.1016\/S0008-4182(05)80078-X"},{"key":"2055_CR8","doi-asserted-by":"crossref","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","DOI":"10.1056\/NEJMoa054481"},{"key":"2055_CR9","doi-asserted-by":"crossref","unstructured":"Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ. 2010;340:c2459.\u00a0","DOI":"10.1136\/bmj.c2459"},{"key":"2055_CR10","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","volume":"121","author":"A Tufail","year":"2014","unstructured":"Tufail A, Xing W, Johnston R, et al. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology. 2014;121:1092\u2013101.","journal-title":"Ophthalmology"},{"key":"2055_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS. Intravitreal aflibercept injection for neovascular age- related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193\u2013201.","journal-title":"Ophthalmology"},{"issue":"9","key":"2055_CR12","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","volume":"124","author":"PU Dugel","year":"2017","unstructured":"Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, Singerman L. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology. 2017;124(9):1296\u2013304.","journal-title":"Ophthalmology"},{"key":"2055_CR13","unstructured":"European Medicines Agency. Workshop on Identifying Opportunities for \u201cbig Data\u201d in Medicines Development and Regulatory Science. E.M.A, 2016.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/report\/report-workshop-identifying-opportunities-big-data-medicines-development-regulatory-science_en.pdf. Accessed 2 Aug\u00a02021."},{"key":"2055_CR14","unstructured":"Use of Real-world Evidence to Support Regulatory Decision-making for Medical Devices: Draft Guidance for Industry and Food and Drug Administration Staff. F.D.A, 2016.\u00a0https:\/\/www.fda.gov\/media\/99447\/download. Accessed 2 Aug\u00a02021."},{"key":"2055_CR15","unstructured":"Ranibizumab and Pegaptanib for the Treatment of Age-related Macular Degeneration. NICE.\u00a02008.\u00a0https:\/\/www.nice.org.uk\/guidance\/ta155. Accessed 2 Aug\u00a02021."},{"key":"2055_CR16","unstructured":"Aflibercept Solution for Injection for Treating Wet Age-related Macular Degeneration. NICE.\u00a02013.\u00a0https:\/\/www.nice.org.uk\/guidance\/ta294. Accessed 2 Aug\u00a02021."},{"key":"2055_CR17","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/eye.2016.149","volume":"30","author":"G Liew","year":"2016","unstructured":"Liew G, Lee AY, Zarranz-Ventura J, Stratton I, Bunce C, Chakravarthy U, Lee CS, Keane PA, Sim DA, Akerele T, McKibbin M, Downey L, Natha S, Bailey C, Khan R, Antcliff R, Armstrong S, Varma A, Kumar V, Tsaloumas M, Mandal K, Egan C, Johnston RL, Tufail A. The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care. Eye (Lond). 2016;30:1462\u20138.","journal-title":"Eye (Lond)"},{"key":"2055_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40258-016-0275-9","volume":"15","author":"T Butt","year":"2017","unstructured":"Butt T, Tufail A, Rubin G. Health state utility values for age-related macular degeneration: review and advice. Appl Health Econ Health Pol. 2017;15:23\u201332.","journal-title":"Appl Health Econ Health Pol"},{"key":"2055_CR19","doi-asserted-by":"crossref","unstructured":"Corazza P, Kabbani J, Soomro T, Alam MMR, D'Alterio FM, Younis S. Three-year real-world outcomes of intravitreal anti-VEGF therapies in patients affected by myopic choroidal neovascularization. Eur J Ophthalmol. 2020:1120672120963455.","DOI":"10.1177\/1120672120963455"},{"key":"2055_CR20","doi-asserted-by":"crossref","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-98.\u00a0","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"2055_CR21","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"2055_CR22","doi-asserted-by":"crossref","unstructured":"Arevalo JF, Lasave AF, Wu L, Ac\u00f3n D, Berrocal MH, Diaz-Llopis M, Gallego-Pinazo R, Serrano MA, Alezzandrini AA, Rojas S, Maia M, Lujan S; Pan-American Collaborative Retina Study Group (PACORES). INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: 5-Year Results of The Pan-American Collaborative Retina Study Group. Retina. 2016;36(5):859\u201367.","DOI":"10.1097\/IAE.0000000000000827"},{"key":"2055_CR23","doi-asserted-by":"crossref","unstructured":"Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;8(8):CD005139.","DOI":"10.1002\/14651858.CD005139.pub3"},{"key":"2055_CR24","doi-asserted-by":"crossref","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57\u201365.e5.","DOI":"10.1016\/j.ophtha.2008.10.018"},{"key":"2055_CR25","doi-asserted-by":"crossref","unstructured":"Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010;150(3):315\u2013324.e1.\u00a0","DOI":"10.1016\/j.ajo.2010.04.011"},{"key":"2055_CR26","doi-asserted-by":"crossref","unstructured":"Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181\u201392.\u00a0","DOI":"10.1016\/j.ophtha.2014.05.009"},{"issue":"8","key":"2055_CR27","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1097\/IAE.0000000000001753","volume":"38","author":"VL Qin","year":"2018","unstructured":"Qin VL, Young J, Silva FQ, et al. Outcomes of patients with exudative age-related macular degeneration treat with antivascular endothelial growth factor therapy for three or more years: A review of current outcomes. Retina. 2018;38(8):1500\u20138.","journal-title":"Retina"},{"key":"2055_CR28","doi-asserted-by":"crossref","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016;123(8):1751\u201361.","DOI":"10.1016\/j.ophtha.2016.03.045"},{"key":"2055_CR29","doi-asserted-by":"crossref","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292\u20139.","DOI":"10.1016\/j.ophtha.2013.03.046"},{"key":"2055_CR30","doi-asserted-by":"crossref","unstructured":"Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, Tuomi L. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119(6):1175\u201383.\u00a0","DOI":"10.1016\/j.ophtha.2011.12.016"},{"key":"2055_CR31","doi-asserted-by":"crossref","unstructured":"Amoaku W, Balaskas K, Cudrnak T, Downey L, Groppe M, Mahmood S, Mehta H, Mohamed Q, Mushtaq B, Severn P, Vardarinos A, Yang Y, Younis S. Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group. Clin Ophthalmol. 2018;12:1731\u201340.","DOI":"10.2147\/OPTH.S174560"},{"issue":"14","key":"2055_CR32","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.2147\/OPTH.S275977","volume":"14","author":"H Mehta","year":"2020","unstructured":"Mehta H, Kim LN, Mathis T, Zalmay P, Ghanchi F, Amoaku WM, Kodjikian L. Trends in Real-World Neovascular AMD Treatment Outcomes in the UK. Clin Ophthalmol. 2020;14(14):3331\u201342.","journal-title":"Clin Ophthalmol"},{"issue":"2020","key":"2055_CR33","first-page":"7465270","volume":"25","author":"Y Gayadine-Harricham","year":"2020","unstructured":"Gayadine-Harricham Y, Rufin V, Law-Koune S, Tran THC. Four-Year Outcome of Aflibercept Treatment-Na\u00efve Patients for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting. J Ophthalmol. 2020;25(2020):7465270.","journal-title":"J Ophthalmol"},{"issue":"8","key":"2055_CR34","doi-asserted-by":"publisher","first-page":"e757","DOI":"10.1111\/aos.13157","volume":"94","author":"MR Munk","year":"2016","unstructured":"Munk MR, Ceklic L, Ebneter A, Huf W, Wolf S, Zinkernagel MS. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol. 2016;94(8):e757\u201364.","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"2055_CR35","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3390\/jcm9051522","volume":"9","author":"AA Plyukhova","year":"2020","unstructured":"Plyukhova AA, Budzinskaya MV, Starostin KM, Rejdak R, Bucolo C, Reibaldi M, Toro MD. Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies. J Clin Med. 2020;9(5):1522.","journal-title":"J Clin Med"},{"key":"2055_CR36","doi-asserted-by":"crossref","unstructured":"Adrean SD, Chaili S, Ramkumar H, Pirouz A, Grant S. Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol. Ophthalmology. 2018;125(7):1047\u201353.","DOI":"10.1016\/j.ophtha.2018.01.012"},{"key":"2055_CR37","doi-asserted-by":"crossref","unstructured":"Engelbert M, Zweifel SA, Freund KB. \"Treat and extend\" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization\/retinal angiomatous proliferation. Retina. 2009;29(10):1424\u201331.\u00a0","DOI":"10.1097\/IAE.0b013e3181bfbd46"},{"issue":"2","key":"2055_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13548506.2016.1274040","volume":"23","author":"J Boyle","year":"2018","unstructured":"Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23(2):127\u201340.","journal-title":"Psychol Health Med"},{"key":"2055_CR39","doi-asserted-by":"crossref","unstructured":"Invernizzi A, Nguyen V, Teo K, Barthelmes D, Fung A, Vincent A, Gillies M. Five-Year Real-World Outcomes of Occult and Classic Choroidal Neovascularization: Data From the Fight Retinal Blindness! Project. Am J Ophthalmol. 2019;204:105\u201312.","DOI":"10.1016\/j.ajo.2019.03.001"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-02055-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-021-02055-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-02055-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T11:20:45Z","timestamp":1673090445000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-021-02055-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,14]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2055"],"URL":"https:\/\/doi.org\/10.1186\/s12886-021-02055-6","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,14]]},"assertion":[{"value":"15 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study of patient data was approved by the Institutional Review Board and ethics committee of Imperial College Healthcare NHS Trust and complied with the guidelines of the Declaration of Helsinki. Informed consent was obtained from all participants in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no financial\/conflicting interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"300"}}